DEXA sales pace Hologic revenues
Bone densitometry firm Hologic enjoyed a strong fiscal 1996 thanksto higher sales of its Acclaim series of dual-energy x-ray bonedensitometers. The Waltham, MA, company's acquisition of miniC-arm manufacturer FluoroScan Imaging Systems also contributedto
Bone densitometry firm Hologic enjoyed a strong fiscal 1996 thanksto higher sales of its Acclaim series of dual-energy x-ray bonedensitometers. The Waltham, MA, company's acquisition of miniC-arm manufacturer FluoroScan Imaging Systems also contributedto Hologic's revenue growth.
For the year (end-September), Hologic posted revenues of $91.6million, up 62% compared with sales of $56.5 million in fiscal1995. The company's net income for the year stood at $11.4 million,compared with $3.3 million the year before, when a legal battlewith Lunar squeezed Hologic's profits.
For the fourth quarter, Hologic had revenues of $24.4 million,up 46% compared with sales of $16.7 million in the fourth quarterof 1995. The company's net income was $2.1 million, compared with$988,000 in the same period a year ago.
While the FluoroScan acquisition added over $3 million in salesto Hologic's fourth quarter, most of the company's growth camethrough sales in the bone densitometry segment: Hologic's revenuein the period would have grown 64% without the FluoroScan acquisition.Sales of Acclaim systems reached record levels in the U.S. dueto new drugs for treating osteoporosis, according to Hologic chairmanand CEO David Ellenbogen.
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.
